Full-Time

Sterile Manufacturing Operator

Engineering

Updated on 8/24/2026

Deadline 8/28/26
Pfizer

Pfizer

10,001+ employees

Biopharmaceutical company develops medicines and vaccines

Compensation Overview

$27.36/hr

+ Overtime pay + Weekend pay premiums + Holiday pay premiums + Other pay premiums

No H1B Sponsorship

Rochester, MI, USA

In Person

On-premise work; schedule is 3:00 p.m. to 11:30 p.m., with overtime and possible six- to seven-day operations.

Bachelor's

Category
Operations & Logistics (1)
Required Skills
CAD
GMP
Data Analysis

Get referred to Pfizer

See people who can refer or advise you

Requirements
  • A High School Diploma or GED and at least two years of experience are required.
  • Understanding of basic problem-solving methods, mathematics, and reading is required.
  • Understanding of Good Manufacturing Practices, including current Good Manufacturing Practices, and Batch Record comprehension is required.
  • Strong communication and leadership skills are required.
  • Ability to contribute to department success in a team environment is required.
  • Ability to perform tasks at a productive level under demanding conditions is required.
  • A solid understanding of procedures, techniques, tools, materials, and equipment is required.
  • The candidate cannot be allergic to penicillin and must undergo penicillin allergy testing.
  • The candidate must be able to bend, reach, lift, and stand for extended periods.
  • The candidate must be able to grasp four to five filled syringes in one hand while manipulating them with the other hand for defect evaluation.
  • Corrected 20/20 vision, including color vision, and the ability to pass a routine inspection test using seeded syringes are required.
  • The candidate must be available for extended hours and six- to seven-day operations when required.
  • The candidate must be authorized to work in the United States by any employer and maintain permanent United States work authorization.
Responsibilities
  • Perform all tasks outlined in the Batch Card, standard operating procedures, and Job Aids.
  • Demonstrate understanding of the standard operating procedures and Job Aids pertinent to assigned tasks.
  • Inspect filled syringes against established criteria and sort defects into the appropriate receptacle for reconciliation.
  • Perform manual packaging operations according to the applicable standard operating procedure or Job Aid.
  • Observe all standard operating procedures and Safety and Health Regulations.
  • Restock packaging supplies from line stock as required to maintain packaging operations.
  • Notify the supervisor, PMO, or Quality Specialist of unusual or recurring defects in syringe products or packaging materials.
  • Maintain a clean and orderly work area.
  • Assist in training new colleagues as required.
  • Verify packaging supplies and product against the product board or Batch Card when required.
  • Sign pertinent forms as required.
  • Participate in required training programs to maintain the required level of current Good Manufacturing Practices compliance.
  • Perform off-line product inspection, such as media reading, when required.
  • Perform other duties assigned by the supervisor.
  • Provide technical and business support to engineers on various tasks.
  • Prepare engineering documentation, reports, and drawings.
  • Conduct preliminary analyses of trajectory adequacy data and ensure model dimensional consistency.
  • Make quantitative judgments on technical data and conduct tests to assist in engineering evaluations.
  • Complete individual contributions and coordinate with others to achieve team deliverables.
  • Follow standard procedures to complete tasks within agreed timeframes.
  • Identify and solve moderately routine problems.
  • Complete assignments with moderate supervision using established procedures and refer deviations to the supervisor.
  • Ensure work is reviewed for accuracy, quality, and adherence to standards.
Desired Qualifications
  • Experience in a pharmaceutical or manufacturing environment is preferred.
  • Proficiency in engineering software and tools is preferred.
  • Knowledge of regulatory requirements and quality standards is preferred.
  • Strong analytical and problem-solving skills are preferred.
  • Organizational and time-management skills are preferred.
  • Ability to prioritize tasks and manage multiple projects simultaneously is preferred.
  • Familiarity with and basic understanding of common artificial intelligence tools, along with curiosity about using them to enhance productivity, is preferred.

Pfizer is a global biopharmaceutical company that discovers, develops, manufactures, and sells medicines and vaccines for a range of health needs, including vaccines, oncology, and other specialized therapies. Its products work by using biological mechanisms to prevent or treat diseases—vaccines train the immune system to fight infections, while medicines target cancer and other conditions. Pfizer differentiates itself through its large worldwide footprint, broad portfolio across multiple therapeutic areas, and partnerships (notably with BioNTech) that expanded its reach in vaccines and cutting-edge therapies. The company also engages in public health initiatives, such as efforts to provide vaccines to underserved populations. Pfizer’s broad goal is to improve global health by delivering safe and effective medicines and vaccines through research, development, and wide international distribution.

Company Size

10,001+

Company Stage

IPO

Headquarters

New York City, New York

Founded

1849

Get referred to Pfizer

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Pfizer raised 2026 revenue guidance to $60.5-$62.5 billion on August 4, 2026.
  • Ex-COVID revenue grew 5% in Q2 2026, driven by Eliquis and Padcev.
  • FDA priority review for Talzenna-Xtandi targets a Q4 2026 approval decision.

What critics are saying

  • Eliquis loses U.S. exclusivity in 2028, threatening Pfizer’s biggest 2026 revenue engine.
  • Paxlovid fell 95% and Comirnaty dropped 34% in Pfizer’s second quarter 2026.
  • If Eliquis replacement and pipeline launches fail, Pfizer becomes a slow-decline cash distributor.

What makes Pfizer unique

  • Pfizer pairs Eliquis scale with oncology assets like Padcev and Talzenna in 2026.
  • Prevnar 20 won Québec public funding in May 2026, deepening vaccine franchise access.
  • Pfizer and Valneva’s Lyme vaccine moved into EMA review on August 14, 2026.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

401(k) Retirement Plan

401(k) Company Match

Paid Vacation

Paid Sick Leave

Paid Holidays

Hybrid Work Options

Relocation Assistance

Growth & Insights and Company News

Headcount

6 month growth

-4%

1 year growth

-4%

2 year growth

-4%
Yahoo Finance
Aug 19th, 2026
Intel CEO invests $10M in shares as chipmaker posts 25% revenue growth driven by AI demand

Intel CEO Lip-Bu Tan purchased nearly $10 million worth of shares as part of the chipmaker's recent stock offering, signalling confidence in the company's turnaround. Intel recently reported revenues of $16.1 billion, growing 25% year-over-year, with its Data Centre and AI business unit seeing revenue surge nearly 60% to $6.3 billion. CoStar Group founder and CEO Andrew Florance purchased 83,300 shares totalling roughly $2.5 million. Pfizer CEO Albert Bourla similarly invested, purchasing 38,000 shares for just over $1 million. These insider purchases reflect executives' confidence in their companies' longer-term outlook, with investors often viewing such moves as a positive signal.

Yahoo Finance
Aug 18th, 2026
Two profitable stocks with solid fundamentals and one to ignore

Two companies leverage profitability to outpace competitors, whilst another faces headwinds, according to StockStory's analysis. Primoris, which builds and maintains infrastructure in utility, energy, and civil construction sectors, struggles with a low gross margin of 10.3% reflecting high production costs. The company has seen falling earnings per share over two years and weak free cash flow margin of 2.2% over five years. BrightSpring Health Services, offering home health care and pharmacy services, has posted 23.9% annual revenue growth over two years. Its revenue base of $14.37 billion provides economies of scale. Pfizer's massive $63.7 billion revenue base gives it significant negotiating power. The pharmaceutical giant's adjusted operating margin expanded by 18.5 percentage points over two years, whilst delivering a 17.5% return on capital.

Yahoo Finance
Aug 11th, 2026
Pfizer raises 2026 guidance to $62.5B, but boost relies on Eliquis facing patent expiry

Pfizer reported second-quarter revenue of $15 billion, up 3% year over year, and raised its 2026 revenue guidance to between $60.5 billion and $62.5 billion. However, investors showed limited enthusiasm. The pharmaceutical giant's anticoagulant Eliquis, shared with Bristol Myers Squibb, generated $2.4 billion in quarterly revenue, up 21% year over year. The drug is now Pfizer's best-selling product. The concern is that Eliquis will lose patent exclusivity by the end of the decade. Pfizer's increased reliance on a drug facing imminent generic competition may signal it has yet to identify a suitable replacement. The company is expanding its pipeline, particularly in the GLP-1 market, where its candidate berobenatide is undergoing phase 3 trials after posting strong phase 2 results.

Yahoo Finance
Aug 11th, 2026
Pfizer raises guidance to $62.5B as BioNTech cuts forecast amid $928M loss

Pfizer and BioNTech reported contrasting second-quarter 2026 results as their post-pandemic strategies diverge. While the European Commission authorised their updated COVID-19 vaccine on 29 July, the former partners now face different financial realities. Pfizer posted revenues of $15 billion, up 1% operationally year-over-year. Excluding COVID products, revenue grew 5%, driven by strong performance from Eliquis, Padcev, and other non-COVID products. The company raised full-year revenue guidance by $500 million to $60.5–$62.5 billion and announced productivity initiatives expected to deliver $2.5 billion in additional savings between 2027 and 2029. BioNTech revenues fell 59.5% to €105.6 million as COVID vaccine demand declined. The company reported a net loss of €820.8 million and reduced full-year revenue guidance to €1.6–€1.9 billion. BioNTech maintains €16.6 billion in cash reserves.

Yahoo Finance
Aug 10th, 2026
Pfizer's earnings fall 58%, but dividend appears safe for now

Pfizer reported a 58% decline in net income for the first half of 2024, falling to $2.4 billion from $5.9 billion year-over-year. The decline was largely driven by $3.8 billion in non-cash impairment charges related to in-process research and development assets. Despite the earnings drop, the dividend appears sustainable. Over the past four quarters, Pfizer generated $11 billion in free cash flow, exceeding the approximately $9.8 billion paid in dividends. The company has struggled with growth whilst managing restructuring costs and integrating recent acquisitions. Its second quarter ended 30 June with a $248 million net loss. Pfizer's stock has fallen 44% over five years, though it's up 9% year-to-date. The dividend currently yields 6.4%.